Baseline characteristics by treatment group for modified intent-to-treat population of activated patients
| . | TXA . | Placebo . |
|---|---|---|
| N | 165 | 165 |
| Age (y), mean (SD) | 54.1 (13.0) | 54.3 (13.2) |
| Sex, n (%) | ||
| Male | 92/165 (55.8) | 100/165 (60.6) |
| Female | 73/165 (44.2) | 65/165 (39.4) |
| Race, n (%) | ||
| American Indian or Alaska Native | 3/160 (1.9) | 6/162 (3.7) |
| Asian | 3/160 (1.9) | 13/162 (8.0) |
| Black or African American | 11/160 (6.9) | 14/162 (8.6) |
| Native Hawaiian or Pacific Islander | 3/160 (1.9) | 4/162 (2.5) |
| White | 141/160 (88.1) | 132/162 (81.5) |
| >1 race | 1/160 (0.6) | 5/162 (3.1) |
| Hispanic ethnicity, n (%) | 8/139 (5.8) | 5/132 (3.8) |
| Primary diagnosis, n (%) | ||
| Acute myeloid leukemia | 73/165 (44.2) | 78/165 (47.3) |
| Myelodysplastic syndrome | 21/165 (12.7) | 16/165 (9.7) |
| Non-Hodgkin lymphoma | 17/165 (10.3) | 12/165 (7.3) |
| Myeloma | 9/165 (5.5) | 16/165 (9.7) |
| Acute lymphoblastic leukemia | 11/165 (6.7) | 10/165 (6.1) |
| Other* | 9/165 (5.5) | 10/165 (6.1) |
| Myelofibrosis | 10/165 (6.1) | 7/165 (4.2) |
| Hodgkin lymphoma | 6/165 (3.6) | 6/165 (3.6) |
| Aplastic anemia | 4/165 (2.4) | 5/165 (3.0) |
| Chronic myelogenous leukemia | 5/165 (3.0) | 3/165 (1.8) |
| Chronic lymphocytic leukemia | 0/165 (0.0) | 2/165 (1.2) |
| Therapeutic group, n (%) | ||
| Acute chemo- or immunotherapy without transplant | 66/165 (40.0) | 64/165 (38.8) |
| Allogeneic transplant | 63/165 (38.2) | 65/165 (39.4) |
| Acute autologous transplant | 36/165 (21.8) | 36/165 (21.8) |
| Baseline laboratory values† | ||
| Platelets (1000/µL), mean (SD) n | 20.9 (9.7) 163 | 19.8 (6.9) 162 |
| Hematocrit, mean (SD) n | 26.7 (3.4) 163 | 26.5 (3.3) 162 |
| Serum creatinine (mg/dL), mean (SD) n | 0.72 (0.22) 163 | 0.74 (0.24) 161 |
| ANC (1000/µL), mean (SD) n | 0.5 (1.7) 160 | 1.0 (5.0) 157 |
| . | TXA . | Placebo . |
|---|---|---|
| N | 165 | 165 |
| Age (y), mean (SD) | 54.1 (13.0) | 54.3 (13.2) |
| Sex, n (%) | ||
| Male | 92/165 (55.8) | 100/165 (60.6) |
| Female | 73/165 (44.2) | 65/165 (39.4) |
| Race, n (%) | ||
| American Indian or Alaska Native | 3/160 (1.9) | 6/162 (3.7) |
| Asian | 3/160 (1.9) | 13/162 (8.0) |
| Black or African American | 11/160 (6.9) | 14/162 (8.6) |
| Native Hawaiian or Pacific Islander | 3/160 (1.9) | 4/162 (2.5) |
| White | 141/160 (88.1) | 132/162 (81.5) |
| >1 race | 1/160 (0.6) | 5/162 (3.1) |
| Hispanic ethnicity, n (%) | 8/139 (5.8) | 5/132 (3.8) |
| Primary diagnosis, n (%) | ||
| Acute myeloid leukemia | 73/165 (44.2) | 78/165 (47.3) |
| Myelodysplastic syndrome | 21/165 (12.7) | 16/165 (9.7) |
| Non-Hodgkin lymphoma | 17/165 (10.3) | 12/165 (7.3) |
| Myeloma | 9/165 (5.5) | 16/165 (9.7) |
| Acute lymphoblastic leukemia | 11/165 (6.7) | 10/165 (6.1) |
| Other* | 9/165 (5.5) | 10/165 (6.1) |
| Myelofibrosis | 10/165 (6.1) | 7/165 (4.2) |
| Hodgkin lymphoma | 6/165 (3.6) | 6/165 (3.6) |
| Aplastic anemia | 4/165 (2.4) | 5/165 (3.0) |
| Chronic myelogenous leukemia | 5/165 (3.0) | 3/165 (1.8) |
| Chronic lymphocytic leukemia | 0/165 (0.0) | 2/165 (1.2) |
| Therapeutic group, n (%) | ||
| Acute chemo- or immunotherapy without transplant | 66/165 (40.0) | 64/165 (38.8) |
| Allogeneic transplant | 63/165 (38.2) | 65/165 (39.4) |
| Acute autologous transplant | 36/165 (21.8) | 36/165 (21.8) |
| Baseline laboratory values† | ||
| Platelets (1000/µL), mean (SD) n | 20.9 (9.7) 163 | 19.8 (6.9) 162 |
| Hematocrit, mean (SD) n | 26.7 (3.4) 163 | 26.5 (3.3) 162 |
| Serum creatinine (mg/dL), mean (SD) n | 0.72 (0.22) 163 | 0.74 (0.24) 161 |
| ANC (1000/µL), mean (SD) n | 0.5 (1.7) 160 | 1.0 (5.0) 157 |